IPP Bureau
Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
By IPP Bureau - September 10, 2024
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
Presence of Mpox virus of West African clade 2 confirmed in isolated patient
By IPP Bureau - September 10, 2024
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
By IPP Bureau - September 10, 2024
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Briefs: Wanbury and Bafna Pharmaceuticals
By IPP Bureau - September 10, 2024
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
By IPP Bureau - September 10, 2024
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Aster Health Academy to offer advanced medical courses
By IPP Bureau - September 10, 2024
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
By IPP Bureau - September 10, 2024
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Granules India’s Gagillapur facility completes USFDA inspection with six observations
By IPP Bureau - September 09, 2024
The recent inspection covered both cGMP and PAI processes
Suspected Mpox case under investigation
By IPP Bureau - September 09, 2024
The patient has been isolated in a designated hospital and is currently stable
Briefs: Ami Organics and Dr. Reddy’s Laboratories
By IPP Bureau - September 09, 2024
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
By IPP Bureau - September 09, 2024
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa
By IPP Bureau - September 09, 2024
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Health Ministry approves introduction of new shorter, more efficacious treatment regimen for drug-resistant TB
By IPP Bureau - September 07, 2024
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
Aster CMI Hospital and Coal India provide bone marrow transplants
By IPP Bureau - September 07, 2024
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
KIMS Hospitals, Hyderabad expands into Kerala
By IPP Bureau - September 07, 2024
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
